Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.


TSX:SVA - Post by User

Comment by Redbaron2211on Dec 27, 2021 9:19pm
264 Views
Post# 34264764

RE:RE:RE:RE:RE:RE:Catching breath

RE:RE:RE:RE:RE:RE:Catching breathMercryfilling that sure doesn't fit the narrative that most "smart longs" liked to paint last Jan.  Heavy shorting by those in the bought deal was the thesis and Doug Loe coming out with a PT below the current SP really didnt help in any version.  

Personally I feel profit taking was a major part of it but it's likely a combination of all and natural after such a big move.  

At this point I agree it doesn't matter.   What matters is the data and the fact that it's becoming increasingly scarce as peers have not been successful.  If we don't get a deal near Jan 13th I don't see it having a detrimental effect on price as good data will support the fact that it's becoming increasingly likely near term and spec should contiune to drive the SP. 

 
<< Previous
Bullboard Posts
Next >>